Botulinum toxin A for post-stroke spasticity: Insights from the French National Hospital Discharge Database (2015-2023).

ABSTRACT:

Background

Botulinum neurotoxin type A (BoNT-A) is a well-established treatment for post-stroke spasticity. However, its real-world use remains underexplored. This study evaluated BoNT-A use trends among stroke survivors in France from 2015 to 2023.

Methods

A retrospective cohort study was conducted using data from the French National Hospital Discharge Database. We analyzed stroke hospitalizations and BoNT-A treatment rates by age and care pathway. Among patients presenting with stroke between 2017 and 2019 who survived beyond 6 months post-stroke, we estimated the prevalence of patients with coded post-stroke spasticity, BoNT-A use, and time from stroke onset to spasticity coding and the first BoNT-A injection.

Results

Between 2015 and 2023, 1,170,436 hospitalizatio

SUBMITTER: Bensmail D 

PROVIDER: S-EPMC12449305 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature